Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Champions Oncology (NASDAQ:CSBR) reported record revenue of $9.5 million for the first fiscal quarter ending July 31, 2020, marking a 42% year-over-year increase. The company achieved income from operations of $421,000 excluding non-cash expenses, reflecting a significant improvement from a loss of $614,000 in the prior year. Operating expenses rose to $9.5 million, up 29.5% year-over-year. The firm ended the quarter with a strong cash position of $6.9 million and no debt, bolstering its long-term growth prospects.
Champions Oncology, Inc. (NASDAQ:CSBR) will release its first-quarter financial and operational results on September 14, 2020, after market close. A conference call is scheduled for 4:30 p.m. EDT on the same day to discuss these results. The call can be accessed by dialing 877-407-8035 domestically or 201-689-8035 internationally. The company specializes in technology solutions for oncology drug development, utilizing its platform to personalize cancer care and improve drug development processes. Further information is available on their website.